Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Meeting Report
  • Published:

The Second International Meeting on Allogeneic Transplantation in Solid Tumors

Bone Marrow Transplantation volume 38, pages 527–537 (2006)Cite this article

Abstract

In October 2005, the second international meeting on allogeneic transplantation in solid tumors was convened in Stresa (Italy). The aim of this second meeting was to share clinical experiences of allografting in solid tumors, to discuss preclinical data on the mechanisms of graft-versus-tumor (GVT) effect, and to review methods for more efficacious transplant approaches. On the first day, the most recent results in cancer immunotherapy were reviewed; head-to head comparisons of clinical results achieved by standard therapy and by allografting in renal, breast, and ovarian cancer were presented. On the second day, GVT mechanisms and preclinical models were examined; anecdotal reports of a GVT effect in sarcoma, pancreatic cancer, prostate cancer, colorectal cancer and lung cancer were presented; new strategies for optimizing transplant outcome were discussed, including patient selection, tumor debulking, auto–allo approaches, selective T-cell depletion, targeting with monoclonal antibodies, use of killer cell immunoglobulin-like receptor-ligand mismatched natural killer cells. In conclusion, allografting in solid tumors is feasible with limited toxicities and transplant-related mortality; a GVT effect has been documented in many different solid tumors; targeting of the immune response to the tumor by new strategies and identification of the target antigen(s) of the GVT effect are promising areas of research.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Allogeneic hematopoietic cell transplantation for solid tumors. Haematologica 2002; 87 (Suppl. 1 to n.6): 1–33.

  2. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318–320.

    Article  Google Scholar 

  3. Rosenberg SA, Yang JC, Restifo NP . Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909–915.

    Article  CAS  Google Scholar 

  4. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–2357.

    Article  CAS  Google Scholar 

  5. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907–912.

    Article  CAS  Google Scholar 

  6. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174: 2591–2601.

    Article  CAS  Google Scholar 

  7. Battaglia M, Stabilini A, Roncarolo MG . Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743–4748.

    Article  CAS  Google Scholar 

  8. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  Google Scholar 

  9. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.

    Article  CAS  Google Scholar 

  10. Rini BL, Zimmerman T, Stadler WM, Gajeski TF, Vogelzang NJ . Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017–2024.

    Article  Google Scholar 

  11. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Reduced-intensity hematopoietic cell allografting and escalating-dose donor lymphocyte infusions in advanced renal and breast cancer. Blood 2002; 99: 4234–4236.

    Article  CAS  Google Scholar 

  12. Pedrazzoli P, Da Prada GA, Georgiani G, Schiavo R, Zimbelli A, Girali E et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409–2415.

    Article  Google Scholar 

  13. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253–261.

    Article  CAS  Google Scholar 

  14. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829–3836.

    Article  CAS  Google Scholar 

  15. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 2004; 32: 599–606.

    Article  Google Scholar 

  16. Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004; 34: 309–316.

    Article  CAS  Google Scholar 

  17. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435–441.

    Article  CAS  Google Scholar 

  18. Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799–7811.

    Article  CAS  Google Scholar 

  19. Artz AS, Van Biesen K, Zimmerman T, Gajewski TF, Rini BI, Hu HS et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: the University of Chicago Experience. Bone Marrow Transplant 2005; 35: 253–260.

    Article  CAS  Google Scholar 

  20. Artz AS, Kocherginsky M, Van Besien K . Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2006; 132: 747–754.

    Article  Google Scholar 

  21. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886–3892.

    Article  Google Scholar 

  22. Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH . Co-stimulated/Tc2 cells abrogate murine marrow graft rejection. Biol Blood Marrow Transplant 2004; 10: 604–613.

    Article  CAS  Google Scholar 

  23. Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH . CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 2003; 102: 3439–3446.

    Article  CAS  Google Scholar 

  24. Slavin S . Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation. Acta Haematologica 2005; 114: 214–220.

    Article  Google Scholar 

  25. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018–1023.

    Article  CAS  Google Scholar 

  26. Satoh M, Miyamura K, Yamada M, Ishidoya S, Childs RW, Arai Y . Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma. Lancet Oncol 2004; 5: 125–126.

    Article  Google Scholar 

  27. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435–441.

    Article  CAS  Google Scholar 

  28. Michalek J, Collins RH, Durrani HP, Vaclavkova P, Ruff LE, Douek DC et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 2003; 100: 1180–1184.

    Article  CAS  Google Scholar 

  29. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123–1129.

    Article  CAS  Google Scholar 

  30. Slavin S, Shapira MY, Morecki S, Samuel S, Ackerstein A, Gelfand Y et al. Immunotherapy for resistant hematologic malignancies using matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ after allogeneic stem cell transplantation for allogeneic cell therapy without GVHD. Blood 2003; 102: 400b (Abs#5329).

  31. Slavin S, Morecki S, Shapira M, Bitan S, Samuel A, Ackerstein A et al. Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation. Am Soc Clin Oncol 2004; 23: 560 (Abs#6516).

    Google Scholar 

  32. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  Google Scholar 

  33. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy Jr JP, Takahashi Y et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004; 104: 170–177.

    Article  CAS  Google Scholar 

  34. Ringdén O, Söderdahl G, Mattsson J, Uzunel M, Remberger M, Hentschke P et al. Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation 2000; 69: 2043–2048.

    Article  Google Scholar 

  35. Söderdahl G, Barkholt L, Hentschke P, Mattsson J, Uzunel M, Ericzon BG et al. Liver transplantation followed by adjuvant nonmyeloablative hematopoietic stem cell transplantation for advanced primary liver cancer in humans. Transplantation 2003; 75: 1061–1066.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the sponsors that have made possible this meeting, and all the Speakers, the Chairmen and the Organizing Secretariat. A special thanks to EBMT Solid Tumor Working Party and to its chairman, Dr Taner Demirer, for the patronage of this event.

Author information

Authors and Affiliations

  1. Department of Oncology, Oncology-Hematology-Bone Marrow Transplant Unit, Istituto Scientifico San Raffaele, San Raffaele Hospital, Milan, Italy

    M Bregni

  2. Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    N T Ueno

  3. NHLBI, National Institutes of Health, Bethesda, MD, USA

    R Childs

Authors
  1. M Bregni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N T Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Childs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Bregni.

Additional information

Note added in proof

The report by Rini et al. referenced as ‘in press’ in Table 1 has been published (Rini BI et al., Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB Intergroup Phase II Study. Biol Blood Marrow Transplant 2006 Jul; 12: 778–785).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bregni, M., Ueno, N. & Childs, R. The Second International Meeting on Allogeneic Transplantation in Solid Tumors. Bone Marrow Transplant 38, 527–537 (2006). https://doi.org/10.1038/sj.bmt.1705479

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705479

Keywords

This article is cited by

Search

Advanced search

Quick links